Enterprise Value
-14.76M
Cash
77.29M
Avg Qtr Burn
-17.05M
Short % of Float
6.09%
Insider Ownership
15.40%
Institutional Own.
55.95%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vidofludimus calcium (IMU-838) Details Multiple sclerosis, Autoimmune disease | Phase 3 Data readout | |
IMU-856 Details Celiac disease | Phase 2b Initiation | |
Vidofludimus calcium (IMU-838) Details Multiple sclerosis, Autoimmune disease | Phase 2 Data readout | |
Vidofludimus calcium (IMU-838) Details Primary sclerosing cholangitis, Bile duct disease, Liver disease | Failed Discontinued | |
Izumerogant (IMU-935) Details Psoriasis | Failed Discontinued | |
Vidofludimus calcium (IMU-838) Details COVID-19, Infectious disease | Failed Discontinued | |
Vidofludimus calcium (IMU-838) Details Inflammatory bowel disease, Bowel disorder, Ulcerative colitis | Failed Discontinued |